Nektar Therapeutics
To see an up-to date selection of historical analyses and insights on
Nektar Therapeutics,
visit our
new, dynamically updated Company Summary report pages for Nektar Therapeutics.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Nektar Therapeutics are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Nektar Therapeutics,
or on any other Company covered by EvaluatePharma® Contact Us today.
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| MAP Pharmaceuticals Announces FDA will not Require a Second Pivotal Efficacy Study for LEVADEX(TM) NDA Submission
|
(MAP Pharmaceuticals)
|
(Invalid Date)
|
| UCB Announces Initial Clinical Trial Results Involving Patients Taking Certolizumab Pegol for Moderate to Severe Crohn’s Disease
|
(UCB)
|
(Invalid Date)
|
| Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program
|
(Affymax)
|
(Invalid Date)
|
| Daiichi Sankyo Launches New Phase 3 Trial with CS-8958 for Flu Prevention
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Phase III Trial With CS-8958 for Flu Prevention Underway
|
(Biota)
|
(Invalid Date)
|
| Affymax and Takeda Announce Hematide(TM) Publication in the New England Journal of Medicine
|
(Affymax)
|
(Invalid Date)
|
| U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
|
(Schering-Plough)
|
(Invalid Date)
|
| Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide(TM) Increased Hemoglobin in Dialysis Patients
|
(Affymax)
|
(Invalid Date)
|
| MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
|
(MAP Pharmaceuticals)
|
(Invalid Date)
|
| Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| Phase 2 Data from Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
|
(AstraZeneca)
|
(Invalid Date)
|
| Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting
|
(Schering-Plough)
|
(Invalid Date)
|
| Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| UCB's Cimzia®, the Only PEGylated Anti-TNF, Approved in Europe
|
(Enzon Pharmaceuticals)
|
(Invalid Date)
|
| Cimzia®, the Only PEGylated anti-TNF, Approved in Europe and Available in a Syringe Designed in Partnership with OXO Good Grips®
|
(UCB)
|
(Invalid Date)
|
| PEGINTRON® Receives a Recommendation for Approval from FDA Advisory Committee for a New Application in Melanoma
|
(Enzon Pharmaceuticals)
|
(Invalid Date)
|
| FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
|
(Schering-Plough)
|
(Invalid Date)
|
| NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| 'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile
|
(MAP Pharmaceuticals)
|
(Invalid Date)
|
| Nektar nearing end of road to recovery
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data to be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
|
(MAP Pharmaceuticals)
|
(Invalid Date)
|
| Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
|
(Affymax)
|
(Invalid Date)
|
| Positive Top Line Results from Phase III Study (MARVELl) of Anti-influenza Virus Agent 'CS-8958'
|
(Daiichi Sankyo)
|
(Invalid Date)
|
| Biota Holdings Announces Successful Phase III Asian Clinical Trials of Its Second Generation Flu Treatment
|
(Biota)
|
(Invalid Date)
|
| LANI Phase III Clinical Trials in Asia Prove Successful
|
(Biota)
|
(Invalid Date)
|
| Chugai Files NDA for a Renal Anemia Agent R744
|
(Chugai)
|
(Invalid Date)
|
| Affymax Announces Data Monitoring Committee Review of Phase 3 Hematide Program
|
(Affymax)
|
(Invalid Date)
|
| Cimzia®, the Only PEGylated anti-TNF, Recommended for Approval in the EU for Rheumatoid Arthritis
|
(UCB)
|
(Invalid Date)
|
| New Data Showed Cimzia® Provided Rapid and Sustained Clinical Response, and Reinforces Need for Rapid-Acting Treatments for RA
|
(UCB)
|
(Invalid Date)
|
| Affymax Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
|
(Affymax)
|
(Invalid Date)
|
| Lantheus Medical Imaging, Inc. Completes Enrollment of CaRES Registry to Further Evaluate Definity®
|
(Lantheus Medical Imaging)
|
(Invalid Date)
|
| Affymax(R) Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide(TM) Regardless of Patient Baseline Renal Function
|
(Affymax)
|
(Invalid Date)
|
| MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
|
(MAP Pharmaceuticals)
|
(Invalid Date)
|
| XOMA Royalties On CIMZIA(r) Expected to Increase Due to FDA Approval for Moderate to Severe Rheumatoid Arthritis in Adults
|
(XOMA)
|
(Invalid Date)
|
| UCB's Cimzia® (certolizumab Pegol) Approved by the U.S. FDA for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
|
(UCB)
|
(Invalid Date)
|
| UCB's Cimzia(R) Approved in the U.S. for Adult Patients Suffering from Moderate to Severe Rheumatoid Arthritis
|
(Enzon Pharmaceuticals)
|
(Invalid Date)
|
| Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
|
(Schering-Plough)
|
(Invalid Date)
|
| NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| New Lantheus Study Finds Significant Survival Benefit For Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography
|
(Lantheus Medical Imaging)
|
(Invalid Date)
|
| Affymax Reports Phase 2 Sub-Analysis of Hematide(TM) in Hemodialysis Patients
|
(Affymax)
|
(Invalid Date)
|
| FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
|
(Schering-Plough)
|
(Invalid Date)
|
| Nektar Announces Positive Results From Phase 2 Study of Oral NKTR-118 in Patients With Opioid-Induced Constipation (OIC)
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| New Study Published in Journal of the American College of Cardiology Finds Utilization of Contrast Echocardiography With Definity® Improves Patient Diagnosis and Management
|
(Lantheus Medical Imaging)
|
(Invalid Date)
|
| Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors
|
(Nektar Therapeutics)
|
(Invalid Date)
|
| For the First Time, Doctors Can Predict Which Hepatitis B Patients Have the Highest Chance to Achieve Treatment Success With Pegasys
|
(Roche)
|
(Invalid Date)
|
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
